Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II.

Abstract

Since early May 2022, some monkeypox virus (MPXV) infections have been reported from countries where the disease is not endemic. Within 2 months, the number of patients has increased extensively, becoming the most considerable MPXV outbreak described. Smallpox vaccines demonstrated high efficacy against MPXVs in the past and are considered a crucial outbreak control measure. However, viruses isolated during the current outbreak carry distinct genetic variations, and the cross-neutralizing capability of antibodies remains to be assessed. Here we report that serum antibodies elicited by first-generation smallpox vaccines can neutralize the current MPXV more than 40 years after vaccine administration.

• Authors: Elena Criscuolo, Benedetta Giuliani, Roberto Ferrarese, Davide Ferrari, Massimo Locatelli, Massimo Clementi, Nicasio Mancini, Nicola Clementi
• Journal: Journal of medical virology (J Med Virol) Vol. 95 Issue 3 Pg. e28643 (03 2023) ISSN: 1096-9071 [Electronic] United States
• PMID: 36890648 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Chemical References

• Smallpox Vaccine

Topics

• Humans
• Monkeypox virus
• Monkeypox (epidemiology, prevention & control)
• Smallpox
• Smallpox Vaccine (genetics)
• Vaccination